Infinity Pharmaceuticals Inc. (NASDAQ:INFI)‘s stock had its “hold” rating reissued by JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday.

A number of other equities research analysts have also weighed in on the company. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Tuesday, October 18th. Morgan Stanley reiterated a “hold” rating and issued a $1.00 target price on shares of Infinity Pharmaceuticals in a research report on Thursday, August 11th. Wedbush reiterated a “neutral” rating and issued a $1.00 target price (down previously from $1.25) on shares of Infinity Pharmaceuticals in a research report on Tuesday, August 9th. Finally, FBR & Co reiterated a “hold” rating on shares of Infinity Pharmaceuticals in a research report on Wednesday, August 10th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Infinity Pharmaceuticals has a consensus rating of “Hold” and an average price target of $4.56.

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at 1.30 on Thursday. Infinity Pharmaceuticals has a one year low of $0.84 and a one year high of $8.98. The firm’s 50-day moving average is $1.36 and its 200-day moving average is $2.36. The stock’s market capitalization is $64.65 million.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.47. Infinity Pharmaceuticals had a negative return on equity of 125.20% and a net margin of 13.23%. During the same quarter last year, the business earned $0.84 EPS. Equities research analysts forecast that Infinity Pharmaceuticals will post ($0.64) EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in INFI. Rhumbline Advisers increased its position in shares of Infinity Pharmaceuticals by 51.7% in the second quarter. Rhumbline Advisers now owns 81,889 shares of the company’s stock worth $109,000 after buying an additional 27,897 shares during the last quarter. Evercore Wealth Management LLC increased its position in shares of Infinity Pharmaceuticals by 14.0% in the second quarter. Evercore Wealth Management LLC now owns 107,091 shares of the company’s stock worth $142,000 after buying an additional 13,157 shares during the last quarter. BlackRock Inc. increased its position in shares of Infinity Pharmaceuticals by 3,199.4% in the second quarter. BlackRock Inc. now owns 107,958 shares of the company’s stock worth $143,000 after buying an additional 104,686 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Infinity Pharmaceuticals by 62.1% in the second quarter. Alliancebernstein L.P. now owns 112,210 shares of the company’s stock worth $149,000 after buying an additional 43,000 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Infinity Pharmaceuticals by 1.8% in the third quarter. California State Teachers Retirement System now owns 103,977 shares of the company’s stock worth $162,000 after buying an additional 1,800 shares during the last quarter. 79.61% of the stock is owned by institutional investors.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

5 Day Chart for NASDAQ:INFI

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.